News | September 27, 2013

JenaValve Raises $62.5 Million In Venture Funding

JenaValve, TAVI system, heart valve repair, CE Mark, JenaValve CE Mark

September 27, 2013 – JenaValve Technology, Inc. announced that it has raised $62.5 million in a Series C venture round.

The financing was led by Belgium-based Gimv. Other new investors include Beijing-based Legend Capital, a venture capital arm of Legend Holdings, Ltd. and an active investor in life sciences as well as Omega Funds, an international healthcare focused investment firm.

Edmond de Rothschild Investment Partners of Paris led the participation by the existing investor group in the Series C round. Other current investors participating in the round included Atlas Venture Fund, NeoMed Management, VI Partners AG and Sunstone Capital A/S.

"JenaValve is gaining momentum in the European TAVI market with our novel transapical TAVI system primarily based on our products' unique features and clinical benefits," said Helmut J. Straubiger, CEO of JenaValve Technology. "We are at an exciting point in our Company's growth as we commence a clinical study for our new transfemoral TAVI product and endeavor to significantly increase revenue in 2013, and beyond, from our transapical product across Europe and other global markets.”

In addition to funding clinical trials and expansion of commercial infrastructure, the Company also announced that it plans to pursue clinical initiatives in the United States as well as pursue regulatory approval for its TAVI product in China.

Gimv Partner Patrick Van Beneden said, "Transcatheter valve implantation is a proven and dynamic market worldwide and JenaValve is delivering a series of compelling new TAVI products that provide benefits over older generations of the technology. We are pleased with the opportunity to contribute as a partner in this endeavor."

Legend Capital Managing Director Ouyang Xiangyu stated, "Our fund has begun to put more emphasis on investments in global life science companies that have a clear China strategy. JenaValve is an excellent fit with our strategy to invest in emerging companies in a fast growing segment, backed by solid clinical evidence with a desire to tap into an unmet need for a large subset of patients in China."

For more information, visit www.jenavalve.com


Related Content

News | Heart Valve Technology

May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the ...

Home May 02, 2025
Home
News | Heart Valve Technology

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for ...

Home April 29, 2025
Home
News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
News | Heart Valve Technology

Jan. 25, 2025—A new study presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that ...

Home January 27, 2025
Home
News | Heart Valve Technology

Jan. 6, 2025 — Medtronic plc has announced it received CE (Conformité Européenne) Mark for the Harmony Transcatheter ...

Home January 06, 2025
Home
News | Heart Valve Technology

Sept. 1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid ...

Home September 04, 2024
Home
News | Heart Valve Technology

June 27, 2024 — The sheer scale of undiagnosed heart valve disease in our aging population has been revealed for the ...

Home June 27, 2024
Home
Subscribe Now